目的:探究全程化药学服务在慢性病患者长期合理用药中的应用.方法:选取 2020 年12 月至2022 年 12 月玉山县黄家驷医院诊治的慢性病患者 80 例为研究对象,随机分为施行常规用药指导的对照组 40 例及施行全程化药学服务的观察组 40 例.分别于干预前、干预后采用Morisky依从性问卷(8-item Morisky Medication Adherence Scale,MMAS-8)、WHO生存质量量表(Methods:The WHO Quality of Life Brief Scale,WHOQOL-BREF)评估依从性及生活质量的变化,并记录用药期间安全性(用药期间出现的总不良反应).结果:与干预前相比,干预 1 m及 3 m后各治疗组的MMAS-8 评分均明显增加(P＜0.05),其中以观察组更为显著(P＜0.05);与干预前相比,干预后各治疗组WHOQOL-BREF评分(生理、心理、社交及环境评分)均明显增加(P＜0.05),其中以观察组更为显著(P＜0.05);干预期间,观察组患者不良反应发生率(2.50%)低于对照组(17.50%),差异有统计学意义(P＜0.05).结论:经对比分析发现全程化药学服务用于慢性病患者院外长期合理用药中,不仅能提高患者治疗依从性,还能降低不良反应发生风险,对于提高生活质量水平也具有积极作用.
Application of whole-process pharmaceutical services in long-term rational drug use among patients with chronic diseases
Objective:To explore the application of whole-process pharmaceutical services in long-term rational drug use among patients with chronic diseases.Methods:Eighty patients with chronic diseases who were diagnosed and treated at Yushan County Huang Jiasi Hospital from December 2020 to December 2022 were selected as the study subjects.They were randomly divided into the control group(40 patients receiving conventional drug use guidance)and the observation group(40 patients receiving whole-process pharmaceutical services).The 8-item Morisky Medical Compliance Scale(MMAS-8)and the WHO Quality of Life Brief Scale(WHO QOL-BREF)were used to evaluate compliance and quality of life before and after intervention.The safety of medication(total incidence of adverse reactions during medication)was recorded.Results:After 1 month and 3 months of intervention,the MMAS-8 scores of both groups increased significantly(P<0.05),and the increases in the observation group were greater(P<0.05).After intervention,the WHOQOL-BREF scores for physiological,psychological,social,and environmental domains of both groups increased significantly(P<0.05),and the increases in the observation group were greater(P<0.05).The incidence of adverse reactions in the observation group(2.50%)was lower than that in the control group(17.50%),and the difference was statistically significant(P<0.05).Conclusion:Applying whole-process pharmaceutical services in long-term rational drug use among patients with chronic diseases can not only improve their treatment compliance,but also reduce the risk of adverse reactions and improve the quality of life.
Whole-process pharmaceutical serviceChronic diseaseRational drug useCompliance
NETL
NSTL
万方数据
